Dr. Reddy's Laboratories has reported results for second quarter ended September 30, 2020.
The company has reported 64.76% fall in its net profit of Rs 481.00 crore for the quarter under review as against net profit of Rs 1365.10 crore for the same quarter in the previous year. Total income of the company decreased 4.27% at Rs 3372.40 crore for Q2FY21 as compared Rs 3522.70 crore for the corresponding quarter previous year.
On the consolidated basis, the company has reported 30.27% fall in its net profit of associate at Rs 771.80 crore for the quarter under review as against net profit of Rs 1106.80 crore for the same quarter in the previous year. However, total income of the company increased by 1.96% at Rs 4962.10 crore for Q2FY21 as compared Rs 4866.80 crore for the corresponding quarter previous year.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1865.95 |
| Dr. Reddys Labs. | 1339.35 |
| Cipla | 1456.95 |
| Zydus Lifesciences | 1108.85 |
| Lupin | 2396.50 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: